EDMONTON, Nov. 15, 2010 (Canada NewsWire via COMTEX) --
Cyplasin Biomedical ( CPBM | PowerRating: OTCBB and XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.
The Company has ordered an initial amount of the Ribavirin API in order to develop various formulations of its C-Virin product and initiate next step product development activities.
Cyplasin CEO Garth Likes commented, "We are pleased to be able to work with such a high quality company as Aurobindo as this initiates the next step of our overall product development strategy. We are working closely with our partners to expedite the Ribavirin API produced by Aurobindo so to formulate it into the final commercial form of the C-Virin product, thus bringing us that much closer to revenue generation."
ABOUT CYPLASIN: http://www.c-pharma.net/
Cyplasin Biomedical is a publically-traded specialty pharmaceutical company (OTCBB:CPBM) with headquarters in Edmonton, Alberta. Cyplasin has amassed a portfolio of key products for the treatment and prevention of HCV infection, which affects over 4 million people in the U.S. and several hundred million people worldwide.
Cyplasin's technology encompasses the use of recombinant DNA technology to manufacture recombinant cytokines and virus like particles (VLPs). VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as hepatitis C. Cyplasin is using the technology to develop a hepatitis C vaccine (C- Vaxin) to prevent hepatitis C viral infection. The Company is also pursuing a revenue generation strategy by selling highly profitable drugs (C-Virin & C-Pegferon) for use in the hepatitis C market.
About Aurobindo Pharma
Aurobindo Pharma is the market leader in semi-synthetic penicillin
drugs. It has a presence in key therapeutic segments like
cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology,
etc. It has a multi-product portfolio with multi-country manufacturing
facilities, and is becoming a marketing conglomerate across the world.
Aurobindo Pharma created a name for itself in the manufacture of bulk
actives (API's) , its area of core competence.
